In metastatic prostate cancer, the rare-cell populations expressing CK|CD45/CD31 included platelet-coated epi.CTCs, which was determined to be a predictive biomarker for treatment response [24]. The gene discussed is PECAM1; the disease is metastatic prostate carcinoma.